Αρχική World News Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients... World News Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations Από Ogkologos - 22 Οκτωβρίου, 2025 413 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Breaking down changes in NHS cancer waiting times in England 17 Αυγούστου, 2023 DIY Mosquito Traps & Deterrents (That Really Work) 23 Ιουνίου, 2021 CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated... 14 Αυγούστου, 2025 EMA Recommends Granting a Marketing Authorisation for Relugolix 24 Μαρτίου, 2022 Φόρτωση περισσοτέρων HOT NEWS FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or... Utility of Serial ctDNA in Guiding Anti-EGFR Rechallenge in Metastatic Colorectal... Should People With Cancer Be Tested for Hepatitis B? Tebentafusp Shows Promising Clinical Activity with an Acceptable Safety Profile in...